Recent developments include the FDA's issuance of a Complete Response Letter for GTx-104, the company's focus on resubmission efforts, and financial updates reflecting steady progress and liquidity.

• In April 2026, the FDA issued a Complete Response Letter for GTx-104 citing manufacturing and non-clinical data deficiencies but no safety or efficacy concerns, with a Type A meeting scheduled to discuss next steps [N1][S1].
• The company decided in June 2026 to discontinue internal development funding for GTx-102 and GTx-101, focusing resources on GTx-104 [S1].
• Grace Therapeutics reported steady progress and financials as of February 2026, with cash and equivalents of approximately $17 million and a current ratio of 8.1 [N1][S1].
• The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine, with additional favorable clinical and pharmacoeconomic outcomes [N8][N1][S1].
• The NDA for GTx-104 was accepted by the FDA in August 2025 with a PDUFA target date of April 23, 2026, prior to the issuance of the CRL [N3][N1][S1].

Grace Therapeutics has demonstrated clinical progress with its lead candidate GTx-104, including positive Phase 3 trial results showing safety and clinical benefits over oral nimodipine. The injectable formulation addresses significant unmet needs in aSAH treatment, potentially improving patient outcomes and hospital resource utilization. The company holds orphan drug designations that may confer marketing exclusivity and regulatory incentives. Its intellectual property portfolio and proprietary formulation technology create barriers to entry. The company maintains liquidity to support NDA resubmission efforts and has refocused resources on GTx-104, which may streamline development and commercialization efforts.

The company faces significant risks including the FDA's Complete Response Letter citing manufacturing and non-clinical data deficiencies, which may delay or prevent approval of GTx-104. Reliance on third-party contract manufacturing organizations introduces risks related to compliance and supply continuity. The company has discontinued internal development of other pipeline candidates, concentrating risk on a single product. Operating losses and negative cash flows continue, necessitating additional capital raises, which may be uncertain or dilutive. Regulatory approval in multiple jurisdictions is required, and failure to obtain or maintain approvals would limit market potential. Competitive generic or branded therapies may also impact commercial success.

Grace Therapeutics' moat is based on its proprietary drug delivery technologies applied to reformulated existing drugs for rare diseases, supported by a substantial intellectual property portfolio with over 79 granted and pending patents globally. The orphan drug designations for its candidates provide potential marketing exclusivity, regulatory incentives, and barriers to entry. The company's focus on rare diseases with unmet medical needs and the use of the FDA's 505(b)(2) pathway may shorten development timelines compared to novel drugs. Additionally, the clinical data supporting GTx-104's improved safety and pharmacokinetics over existing oral formulations may provide competitive differentiation. However, reliance on third-party manufacturing and regulatory approval risks remain significant.

• Regulatory Approval Risk: The FDA issued a Complete Response Letter for GTx-104 citing manufacturing and non-clinical data deficiencies, which may delay or prevent approval. The company must satisfactorily address these issues and demonstrate compliance to obtain approval.
• Manufacturing Risk: Grace Therapeutics relies on third-party contract manufacturing organizations for drug production. Deficiencies identified by the FDA at the current CMO pose risks of delays, increased costs, or inability to obtain regulatory approval or commercialize GTx-104.
• Financial Risk: The company has incurred operating losses and negative cash flows since inception. Additional capital will be required to support NDA resubmission and potential commercialization, with uncertainty regarding availability and terms of funding.
• Concentration Risk: The company has discontinued internal development of GTx-102 and GTx-101, focusing solely on GTx-104, concentrating development and commercial risk on a single product candidate.
• Market and Competitive Risk: Approval and market acceptance of GTx-104 depend on differentiation from existing oral nimodipine formulations and potential competition from generics or other therapies.

• Grace Therapeutics, Inc. focuses on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies applying proprietary formulations to approved pharmaceutical compounds to improve efficacy, onset, side effects, delivery, and compliance.
• The company’s pipeline includes three unique clinical-stage drug candidates supported by over 79 granted and pending patents worldwide.
• The lead candidate, GTx-104, is a novel injectable formulation of nimodipine for intravenous infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients, designed to overcome limitations of oral nimodipine.
• GTx-104 uses nanoparticle technology to solubilize nimodipine for standard peripheral IV infusion, potentially eliminating nasogastric tube administration and reducing food effects, drug interactions, and dosing errors.
• GTx-104 has been administered to over 200 patients and healthy volunteers, showing good tolerability and lower pharmacokinetic variability compared to oral nimodipine capsules.
• The company completed a Phase 3 STRIVE-ON randomized safety trial comparing GTx-104 to oral nimodipine capsules, meeting its primary endpoint with a 19% reduction in clinically significant hypotension events.
• Additional trial results showed higher dose intensity adherence, improved favorable outcomes on the modified Rankin scale, better quality of life measures, and fewer ICU readmissions and ventilator days for GTx-104 patients.
• The FDA accepted the NDA for GTx-104 in June 2025 with a PDUFA target date of April 23, 2026, but issued a Complete Response Letter (CRL) in April 2026 citing CMC and non-clinical issues, not safety or efficacy.
• The CRL identified additional leachable data requirements, toxicology risk assessments, and cGMP deficiencies at the contract manufacturing organization (CMO).
• A Type A meeting with the FDA was scheduled to clarify the path forward for NDA resubmission.
• The company decided in June 2026 not to resume internal development funding for the other two candidates, GTx-102 and GTx-101, focusing on GTx-104.
• Grace Therapeutics does not own manufacturing facilities and relies on third-party CMOs, which are subject to regulatory scrutiny and audits.
• The company holds orphan drug designation for its three drug candidates, which may provide marketing exclusivity and regulatory incentives if approved.
• Financial figures as of March 31, 2026, include cash and equivalents of $16.98 million, current assets of $17.38 million, current liabilities of $2.15 million, net loss of $7.79 million, and basic and diluted EPS of -$0.47 per share, with a current ratio of 8.1 and cash ratio of 12.47.
• The company has incurred operating losses and negative cash flows since inception and plans to raise additional capital to support commercial launch if GTx-104 is approved.
• The company’s management team has expertise in drug formulation, regulatory affairs, late-stage development, and commercialization, including a neurosurgeon-scientist expert in aSAH.
• The company’s business model centers on reformulating existing drugs for rare diseases using the FDA’s 505(b)(2) regulatory pathway to potentially shorten approval timelines.
• The company’s lead market opportunity is the treatment of aSAH, affecting approximately 42,500 patients annually in the U.S., with additional cases in the EU and China.
• Market research indicates hospital administrators and neuro ICU physicians show 80% likelihood of adopting an IV nimodipine formulation with improved bioavailability and safety.
• The company’s intellectual property portfolio includes 10 U.S. issued patents and 3 pending U.S. applications, supporting barriers to entry and market position.